Understand your trajectory.
Change what comes next.

Peptides are short chains of amino acids. Studying a peptide’s biological effects is different from showing that it produces a meaningful improvement in attention, memory or daily functioning. For Semax, our review asks which patient groups were studied, how outcomes were measured, how long any effects lasted and what safety monitoring was performed. We do not assume findings from one condition apply to ADHD or early cognitive concerns.

Evidence & limitations. Semax is among the peptides Hall Longevity Clinic is beginning to evaluate in its review of early cognitive concerns and ADHD. It is not presented here as an established component of a treatment regimen or as a proven treatment for either condition. FDA’s 2026 review identifies potential immunogenicity concerns, including peptide aggregation and impurities, with proposed injectable and intranasal formulations. Any consideration requires an individualized clinical assessment, a review of the evidence and current regulatory requirements.

These microscopic vesicles carry biological material between cells; they are not living stem cells. Research explores whether their cargo can influence tissue responses. Products can differ substantially by cell source, processing and composition, so “exosomes” does not describe a single standardized treatment. Laboratory mechanisms cannot establish the safety, dose or effectiveness of a marketed product in people.

Evidence & limitations. Exosomes are extracellular vesicles studied for the signals they carry between cells. Laboratory findings do not establish that a commercial exosome product improves memory, attention or cognition in people. FDA reports no approved exosome products and has received reports of serious adverse events with unapproved products.

Muse cells are a distinct cell population studied for their response to tissue injury and capacity to develop characteristics of different cell types. They differ from exosomes: one approach uses cells, while the other uses cell-derived vesicles. The cited nasal-delivery study examined motor recovery after stroke in mice, not memory improvement or ADHD treatment in humans. Those differences are central to interpreting the findings.

Evidence & limitations. Muse (multilineage-differentiating stress-enduring) cells are being investigated for tissue repair. Intranasal research in a mouse stroke model is preclinical evidence—not proof of cognitive improvement in people. Cell source, manufacturing, route and trial population matter; results from one product or route cannot establish the effectiveness of another.

Kurve Therapeutics developed the ViaNase device for intranasal delivery using its Controlled Particle Dispersion technology. Nasal atomization disperses a liquid formulation into small droplets; it is a delivery method, not a therapeutic substance. Kurve’s technology has been used in intranasal research, including studies involving insulin. That work does not validate administering every peptide, cell or exosome product through the device.

Evidence & limitations. Nasal atomizers are devices, not regenerative therapies themselves. A device’s ability to deliver a formulation does not prove that it reaches a therapeutic brain concentration or improves cognition. The exact device, formulation, intended use and regulatory status must be verified separately. This overview does not recommend administering cells, exosomes or injectable peptide products through a nasal device.

Cerebrolysin is a mixture rather than one purified peptide. The porcine designation identifies its animal source; it is not a stem-cell or exosome product. The supplied translation describes neurological indications in a foreign prescribing context, which must not be read as U.S. authorization. Assessing it requires looking beyond proposed mechanisms to controlled clinical outcomes, adverse effects, interactions and the exact formulation.

Evidence & limitations. The supplied translated product information describes a peptide mixture obtained from porcine brain for injection. It is not evidence of FDA approval or of benefit for healthy cognitive enhancement. The document lists important precautions, including seizure disorders, severe renal impairment and hypersensitivity. It does not establish an intranasal use.

Cortexin is also a mixture, not a single peptide, and is distinct from Cerebrolysin despite their shared neurological research context. “Bovine-derived” identifies cattle as the tissue source in the supplied leaflet. Animal origin, manufacturing consistency, allergy risk and product authenticity are relevant review questions. Neither the leaflet’s mechanistic claims nor its foreign indications establish that it prevents cognitive decline or treats ADHD.

Evidence & limitations. The supplied translated leaflet describes polypeptides from cattle cerebral cortex for intramuscular administration. The translation is retailer-provided and requires verification against current manufacturer labeling. Its claims do not establish FDA approval or reliable cognitive-enhancement benefits. Reported risks include serious allergic reactions; it does not establish an intranasal use.